Rhine Biotech announced that the company received a notice from controlling shareholder Qin Benjun on December 8. It is planning a change of control, plans to transfer part of its shares and relinquish part of its voting rights to the Guangzhou Telford Nutrition Agreement, and has signed an agreement of intent. At the same time, the company plans to issue shares and buy at least 80% of Beijing Jinkangpu's shares to raise capital from Guangzhou Defu Nutrition. The transaction or constituted a related transaction. Due to uncertainty about the matter, trading of the company's shares will be suspended from the opening of the market in December 2025 [specific date missing]. Trading is expected to resume for no more than 10 trading days, and trading will resume before December 24 at the latest.

Rhine Biotech announced that the company received a notice from controlling shareholder Qin Benjun on December 8. It is planning a change of control, plans to transfer part of its shares and relinquish part of its voting rights to the Guangzhou Telford Nutrition Agreement, and has signed an agreement of intent. At the same time, the company plans to issue shares and buy at least 80% of Beijing Jinkangpu's shares to raise capital from Guangzhou Defu Nutrition. The transaction or constituted a related transaction. Due to uncertainty about the matter, trading of the company's shares will be suspended from the opening of the market in December 2025 [specific date missing]. Trading is expected to resume for no more than 10 trading days, and trading will resume before December 24 at the latest.